Skip to main content
. 2013 Nov 26;4(12):2487–2501. doi: 10.18632/oncotarget.1604

Fig 8. Y2R antagonist impairs vascularization of ES xenografts.

Fig 8

A. Representative images of immunostaining for endothelial marker, CD31, in SK-ES1 subcutaneous xenografts treated with placebo or Y2R antagonist (10−6M). B. Tumor vascularization of control and Y2R antagonist-treated SK-ES1 xenografts measured by area of CD31 staining. C. mRNA levels of mouse VEGFR2 measured in SK-ES1 xenografts by real-time RT-PCR